Associated Genetic Biomarkers
NCI Definition: A rare, highly aggressive and lethal carcinoma that affects children and young adults. It arises from midline epithelial structures, most commonly the head, neck, and mediastinum. It is a poorly differentiated carcinoma and is characterized by mutations and rearrangement of the NUT gene. A balanced translocation t(15;19) is present that results in the creation of a fusion gene involving the NUT gene, most commonly BRD4-NUT fusion gene. 
There is 1 clinical trial for NUT carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains NUT carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
NUTM1 is the most frequent gene inclusion criterion for NUT carcinoma clinical trials .
Cisplatin, etoposide, and molibresib are the most common interventions in NUT carcinoma clinical trials.
Significant Genes in NUT Carcinoma
NUTM1 is an inclusion eligibility criterion in 1 clinical trial for NUT carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NUTM1 status and NUT carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.